SciSparc

Company Overview

Snapshot

Founded in August 2004, SciSparc operates with 1–10 employees. The company has raised $63.76 million across 12 funding rounds from 1 investor. In October 2025, SciSparc acquired Neurothera Labs.

Business overview

SciSparc is a clinical-stage pharmaceutical company specializing in cannabinoid-based pharmaceuticals. The company develops drug programs utilizing THC and non-psychoactive cannabidiol (CBD) for central nervous system disorders. Its product pipeline includes SCI-110 for Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for pain management; and SCI-210 for autism spectrum disorder and epilepsy. SciSparc operates within the Health Tech & Life Sciences sector, focusing on pharmaceutical development.

Strategic signal

In October 2025, SciSparc announced the closing of its acquisition of Neurothera Labs, a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio. This strategic move indicates SciSparc's intent to consolidate its clinical assets and potentially leverage Neurothera Labs' public listing for broader market access and accelerated development, signaling a significant shift in its operational structure and growth strategy.

Company Intelligence Q&A

What was a significant recent corporate development for SciSparc?

In October 2025, SciSparc announced the closing of the acquisition of a publicly traded company on the TSXV, to which it transferred its advanced clinical-stage pharmaceutical portfolio.

What was the outcome of the N2OFF merger with SciSparc's subsidiary?

In October 2025, N2OFF completed its merger with SciSparc's majority-owned subsidiary MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.

What was a recent regulatory approval for SciSparc's Tourette syndrome treatment?

In September 2024, SciSparc secured FDA green light to launch its pivotal Phase IIb clinical trial for breakthrough Tourette Syndrome Treatment in the US.

What is SciSparc's involvement in quantum computing for drug discovery?

In October 2025, SciSparc resolved to launch an innovative quantum computing-enabled 3D protein modeling initiative to revolutionize AI drug discovery.

What was a recent patent granted to SciSparc?

In October 2023, SciSparc was granted a patent from the Australian Patent Office for its reduction of opioids use in pain management technology.